Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

NCT04354259 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04354259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04354259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2020
Completion date
December 8, 2022
Enrollment
157 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov2